Separating Artificial Intelligence Hype from Real Utility in Drug Development

1:45 PM - 2:40 PM, Wednesday, October 23, 2019 ・ 2nd Floor
Recent data shows venture investment in AI-focused biopharma companies reached a new high of $1.4B through the first half of this year, according to CB Insights. However, the wide variance in applications and algorithms has complicated the ability to map progress in drug development techniques. As leaders in this space now begin to point to molecules moving into development and early clinical results, the prioritization of tools for other biotechs to consider adopting becomes clearer. This session will examine where AI can improve current drug discovery and development versus technological promises that are still years away from delivery.

Moderator: JC Simbana, Senior Vice President, Venture Capital Relationships & Healthcare Banking, Pacific Western Bank
Speakers
photo
Founder & Chief Executive Officer
NuMedii
photo
President and Chief Operating Officer
Blackthorn Therapeutics
photo
President and CEO;Co-Founder
InveniAI; BioXcel Corporation
photo
Senior Vice President, Venture Capital Relationships & Healthcare Banking
Pacific Western Bank (Square 1 Bank)
photo
Chief Executive Officer, Co-founder
Verge Genomics